ProSensa Holding N.V.

81 articles about ProSensa Holding N.V.

• GlaxoSmithKline, ProSensa Holding N.V.'s Muscular Dystrophy Drug Fails in Phase 3 Trial; ProSensa Stock Plunges -70.25% at Market Close on September 20, 2013

  9/23/2013

• ProSensa Holding N.V. Initiates First Patient Dosing in Phase I/II trial of PRO053

  9/6/2013

• ProSensa Holding N.V. Announces Second Quarter 2013 Financial Results and Recent Corporate Developments

  8/28/2013

• ProSensa Holding N.V. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on August 28, 2013

  8/20/2013

• [1} to Present at Wedbush 2013 Life Sciences Management Access Conference

  8/6/2013

• ProSensa B.V. Awarded EUR 6 Million EU FP7 Research Grant

  8/1/2013

• Prosensa Holding N.V. Announces Closing of Initial Public Offering

  7/8/2013

• Statement From CureDuchenne Regarding ProSensa B.V. IPO

  6/28/2013

• ProSensa B.V. Raises $78 Million in IPO

  6/28/2013

• ProSensa B.V. to Present at J.P. Morgan Healthcare Conference

  1/3/2013

• ProSensa B.V. Raises Around $30 Million to Progress Exon-Skipping Antisense Oligonucleotides

  1/25/2012

• ProSensa B.V. Named Most Innovative European Biotech SME

  11/8/2011

• GlaxoSmithKline and ProSensa B.V. Announce Start of Phase III Study of Investigational Duchenne Muscular Dystrophy Medication

  1/19/2011

• ProSensa B.V. Receives £7.5 Million ($11.9 Million) Milestone Payment as Part of Its Program with GlaxoSmithKline in Duchenne Muscular Dystrophy

  10/13/2010

• ProSensa B.V. and GlaxoSmithKline Initiate Development of Four Additional Products Under Existing Alliance in Duchenne Muscular Dystrophy

  6/23/2010

• ProSensa B.V. Initiates Clinical Development of PRO044 in an Open Label Phase I/II Study

  3/30/2010

• GlaxoSmithKline in $680 Million RNA Deal with ProSensa B.V.

  10/14/2009

• ProSensa B.V. Raises E18 Million

  12/18/2008

• CureDuchenne, AVI BioPharma, Inc., And ProSensa B.V. Exon Skipping Hosting Conference for Duchenne Muscular Dystrophy

  10/14/2008

• Leiden University Medical Center and ProSensa B.V. Announce The New England Journal of Medicine Publication of First Successful Clinical Study with RNA-based Therapeutic PRO051 in Duchenne Muscular Dystrophy

  12/27/2007